Peer review reports
From: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial
Original Submission |
2 Nov 2021 |
Submitted |
Original manuscript
|
Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
16 Jan 2022 |
Reviewed |
Reviewer Report
|
12 Mar 2022 |
Author responded |
Author comments - Safa Najafi
|
Resubmission - Version 4 |
12 Mar 2022 |
Submitted |
Manuscript version 4
|
27 Mar 2022 |
Author responded |
Author comments - Safa Najafi
|
Resubmission - Version 5 |
27 Mar 2022 |
Submitted |
Manuscript version 5
|
15 Apr 2022 |
Reviewed |
Reviewer Report
|
1 May 2022 |
Author responded |
Author comments - Safa Najafi
|
Resubmission - Version 6 |
1 May 2022 |
Submitted |
Manuscript version 6
|
7 May 2022 |
Author responded |
Author comments - Safa Najafi
|
Resubmission - Version 7 |
7 May 2022 |
Submitted |
Manuscript version 7
|
6 Jun 2022 |
Reviewed |
Reviewer Report
|
Resubmission - Version 8 |
|
Submitted |
Manuscript version 8
|
Publishing |
14 Jul 2022 |
Editorially accepted |
|
7 Sep 2022 |
Article published |
10.1186/s12885-022-09895-5
|
Learn about peer review